Section 01
Executive Summary
Full longevity platform for men who train
TL;DR
BioForge is a longevity platform for adults 30-55 who are serious about health optimization. We help them recover faster, perform better, and live longer through a free health quiz, blood work with 100+ biomarkers, prescription peptides delivered as pre-filled pens (a first in the industry), and dedicated medical teams. Starting from $0 (free quiz + waitlist) to $999/month (full longevity protocol), with $5-50K/year concierge tiers in the Year 2-3 roadmap. We fill a gap nobody owns: affordable comprehensive testing AND treatment in one place. Blood work ($365 one-time) is the funnel that leads to peptide subscriptions ($299-999/month). We start with $22K (vibe-coded with AI, near-zero tech cost) and target $2-5M revenue in Year 1 through compound reinvestment of gross profit into marketing (payback period < 1 month per customer).
Target Market (TAM)
$7.8T
Year 1 Revenue Target
$2-5M
Year 5 Revenue Target
$80-150M
Initial Investment
$22K
BioForge is a full longevity platform for adults 30-55 who are serious about health optimization and want to perform at their peak for decades. We help people recover faster and live longer through blood tests, personalized recommendations, and prescription peptides — including industry-first pre-filled pens that eliminate needle phobia. Our value ladder: free quiz and waitlist to build hype, $365 blood work + first consultation as the funnel, then peptide subscriptions from $299-999/month. The key financial insight: with $350 CAC and payback period under 1 month, we reinvest 100% of gross profit into marketing — $13K initial ad budget compounds to $750K/month by month 12, driving $2-5M Year 1 revenue. We fill the gap nobody owns: Function Health does testing ($2.5B valuation) but no treatment, Lifeforce does treatment but weak diagnostics, Fountain Life does both but requires physical presence at just 4-6 US centers. BioForge gives comprehensive testing AND treatment, fully remote — blood work at 2,000+ Quest labs, peptides shipped home, telehealth consultations from anywhere. Hims started men-only then added Hers and reached $2.4B — we start gender-inclusive from day 1. Operating from Dubai with AI-first operations (vibe-coded, near-zero tech cost) and outsourced telehealth infrastructure, self-funded with $22K. Year 5 target: $80-150M revenue.
Why Now?
FDA Peptide Reclassification (Feb 2026)
HHS Secretary RFK Jr. announced ~14 of 19 previously banned peptides (BPC-157, TB-500, Thymosin Alpha-1, etc.) will return to legal compounding status under Category 1. This reopens a massive market that was restricted since 2023.
Nobody Owns the Middle Market
Function Health ($2.5B valuation, 100K members) does testing but NO treatment. Lifeforce (Tony Robbins) does treatment but weak diagnostics. Fountain Life does both but is geographically limited to 4-6 US centers. The fully remote, comprehensive testing AND treatment space is wide open.
Medvi Proved the Market Exists
Medvi demonstrated that a 2-person team can generate $401M in revenue (2025) using telehealth-as-a-service infrastructure and AI. The market and infrastructure work. We take the same infrastructure but with ethics, compliance, a better product (pre-filled pens), and a premium brand.
Pre-Filled Pens = First Mover Advantage
NOBODY offers pre-filled pens for BPC-157, TB-500, CJC-1295/Ipamorelin, or Sermorelin. All competitors ship vials + syringes requiring reconstitution. Pens eliminate needle phobia (massive barrier), justify premium pricing (Zepbound pen = $1,086 vs vial = $349-499 = 2-3x premium), and create a defensible differentiator.
AI Cost Reduction + Vibe Coding
AI tools have reduced the cost of building a full-stack DTC brand by 90%+. The entire website/app is vibe-coded with AI at near-zero cost. Quiz funnels achieve 70-80% completion rates and 40-60% lower CPA. What required 50+ employees in 2020 can now be done by 1-2 people with AI. $22K is genuinely enough to launch.
Competitive Advantages
- 1Pre-filled pens for specialty peptides — NOBODY else offers this. First mover advantage with 2-3x pricing premium over vials
- 2Blood work as funnel: $365 one-time includes blood work + first consultation + protocol recommendation — the SOLUTION, not just the problem
- 3Trust-first journey: Quiz → Blood work → First consultation → Single peptide order → Results → THEN subscription
- 4Waitlist model (like Function Health's 500K waitlist) creates scarcity and hype before launch
- 5Gender-inclusive from day 1: Hims started men-only then added Hers to reach $2.4B. We capture the full market immediately
- 6Fully remote vs. geographically limited competitors: 2,000+ Quest labs for blood work, peptides shipped home, telehealth from anywhere
- 7AI-first operations + vibe coding reducing overhead by 90%+ vs. traditional telehealth. $22K start, not $22M
- 8Education-first content strategy for latent demand: "Why do you feel tired at 40?" not "Buy peptides now"
- 9Dubai free zone structure enabling global distribution with 0% corporate tax